TORONTO, June 7 /CNW/ - Amorfix Life Sciences (TSX-V:AMF), a company
focused on diagnostics and treatments for brain wasting diseases, announced
today that Joseph Beckman, Ph.D., will join the Company's Scientific Advisory
Board. Dr. Beckman is an expert in Amyotrophic Lateral Sclerosis (ALS) disease
and the role of superoxide dismutase-1 (SOD1) in this disease. Amorfix's
therapeutic program for ALS targets SOD1.
